Roei Mazor, MD, PhD, Assuta Medical Center, Tel Aviv, Israel, shares some insights into Langerhans cell histiocytosis (LCH) and explains how different subtypes of histiocytosis differ from one another by various factors including the driver oncogene, the clinical presentation, and by the capacity to diverge and to generate a polyclonal phenotype. The different treatment strategies for LCH and malignant histiocytosis are described. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть